Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults
July 20, 2023
July 20, 2024
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)..
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
The educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma.
Patients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be achieved. Many patients with asthma are candidates for biologic therapies, which can significantly improve the burden of disease.
Join a panel of pulmonology and allergy experts, who will discuss patient cases to illustrate disease and management aspect of asthma with comorbidities. Panelists will review the negative impact of uncontrolled moderate‐to‐severe asthma on airway remodeling and lung development in children. Panelists will also discuss conditions that occur frequently with asthma and their shared pathophysiology as a treatment target. Current evidence, including long‐term data and guideline recommendations for asthma treatment will be explored, along with strategies to develop personalized treatment plans for patients based on asthma phenotype, biomarkers, and comorbidities.
After completing this activity, the participant should be better able to:
- Summarize the negative effects of comorbidities on the disease burden of moderate‐to‐severe asthma and on clinicians’ ability to achieve disease control
- Explain the negative consequences of failure to achieve control of moderate‐to‐severe asthma on lung development in children
- Apply current evidence and guidelines to identify appropriate biologic therapies for severe asthma based on phenotype, biomarkers, and comorbidities
Theresa Guilbert, MD, MS
Professor of Pediatrics
Dept of Pediatrics, University of Cincinnati
Director of the Asthma Center
Cincinnati Children’s Hospital Medical Center
Anju T. Peters, MD, MSCI
Professor of Medicine
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Stacey Denham, MSW, MPH
Public Health Manager
Asthma and Allergy Foundation of America (AAFA)
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this activity, please visit https://partnersed.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”